Evidence map›Paper›PMID 27266853›Full record

Trial reportCirculation. Heart failure2016

Combining Diuretic Response and Hemoconcentration to Predict Rehospitalization After Admission for Acute Heart Failure.

Jozine M Ter Maaten, Mattia A E Valente, Kevin Damman, John G Cleland, Michael M Givertz, Marco Metra, Christopher M O'Connor, John R Teerlink, Piotr Ponikowski, Daniel M Bloomfield and 8 more

3 registry-linked trialsAbstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Circulation. Heart failure, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04298229 phase3completedstarted 2020, after this paper: background citation

A Randomized, Open-label Study of Dapagliflozin in Patients With or Without Type 2 Diabetes Admitted With Acute Heart Failure

Ran2020Enrolled240Registered outcomes3Posted comparisons0ConditionsDiabetes Mellitus, Type 2, Heart FailureArmsDapagliflozin 10 mg, Protocolized Diuretic Therapy
PMID 26299229PMID 26041600PMID 25838436PMID 25287144PMID 24879974PMID 24585267PMID 24379278PMID 24247300PMID 23356556PMID 23333145PMID 23141816PMID 21732835other papers from this trial
Open the trial in the graph
NCT00071331 phase3completednot on this map

Protocol 156-03-236: Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Long Term Efficacy and Safety of Oral Tolvaptan Tablets in Subjects Hospitalized With Worsening Congestive Heart Failure

TypeinterventionalSponsorOtsuka Pharmaceutical Development & Commercialization, Inc.Ran2003 to 2006Enrolled3,600ConditionsCongestive Heart FailureArmsTolvaptan
NCT00354458 phase3completednot on this map

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Effects of KW-3902 Injectable Emulsion on Heart Failure Signs and Symptoms and Renal Function in Subjects With Acute Heart Failure Syndrome and Renal Impairment Who Are Hospitalized for Volume Overload and Require Intravenous Diuretic Therapy

TypeinterventionalSponsorNovaCardia, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Ran2006 to 2009Enrolled1,102ConditionsHeart Failure, CongestiveArmsrolofylline, Comparator: Placebo (unspecified)
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Highlights in heart failure.ESC heart failure · 2019
    Pooled it
  2. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.Clinical research in cardiology : official journal of the German Cardiac Society · 2017
    Trial
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Lessons learned in acute heart failure.European journal of heart failure · 2018
    Review
  16. Article
  17. Observational
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Jozine M Ter MaatenFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Mattia A E ValenteFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Kevin DammanFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
John G ClelandFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Michael M GivertzFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Marco MetraFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Christopher M O'ConnorFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
John R TeerlinkFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Piotr PonikowskiFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Daniel M BloomfieldFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Gadi CotterFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Beth DavisonFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Haris SubaciusFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Dirk J van VeldhuisenFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Peter van der MeerFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Hans L HillegeFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Mihai GheorghiadeFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.).
Adriaan A VoorsFrom the Departments of Cardiology (J.M.t.M., M.A.E.V., K.D., D.J.v.V., P.v.d.M., H.L.H., A.A.V.) and Epidemiology (H.L.H.), University of Groningen, University Medical Center Groningen, The Netherlands; University of Hull, Kingston Upon Hull, United Kingdom (J.G.C.); Brigham and Women's Hospital, Boston, MA (M.M.G.); University of Brescia, Italy (M.M.); Inova Heart and Vascular Institute, Falls Church, VA (C.M.O.C.); University of California at San Francisco, San Francisco Veterans Affairs Medical Center, CA (J.R.T.); Medical University, Clinical Military Hospital, Wroclaw, Poland (P.P.); Merck Research Laboratories, Rahway, NJ (D.M.B.); Momentum Research, Durham, NC (G.C., B.D.); University of Iowa Carver College of Medicine Cardiovascular Research Center Iowa City, IA (H.S., M.G.); and Center for Cardiovascular Innovation, Northwestern University Feinberg School of Medicine, Chicago, IL (H.S., M.G.). a.a.voors@umcg.nl.
University Medical Center Groningen · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBoth diuretic response and hemoconcentration are indicators of decongestion and have individually been found to predict rehospitalization after admission for acute heart failure (HF). This study examines the value of combining diuretic response and hemoconcentration to better predict patients at low risk for rehospitalization after admission for acute HF. METHODS AND

resultsDiuretic response (defined as weight change per 40 mg of furosemide on day 4 after admission) and hemoconcentration (change in hemoglobin at discharge or day 7) were tested both individually and combined to predict the risk of HF and cardiovascular rehospitalization 60 days after hospitalization for acute HF. Analyses were performed in 1180 patients enrolled in the Placebo-Controlled Randomized Study of the Selective Adenosine Receptor Antagonist Rolofylline for Patients Hospitalized With Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function (PROTECT) trial and validated in 1776 patients enrolled in the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) trial. Poor diuretic response was associated with low systolic blood pressure, high blood urea nitrogen, and history of coronary revascularization in both data sets (all P<0.05). Hemoconcentration was mainly associated with better renal function (P<0.05). Patients who displayed both favorable diuretic response and hemoconcentration had a markedly lower risk of rehospitalization for HF in PROTECT (multivariable HR, 0.41; 95% CI, 0.24 to 0.70; P<0.001) compared with all other patients. This finding was confirmed in EVEREST (multivariable HR, 0.52; 95% CI, 0.33 to 0.82; P=0.004) for patients with favorable diuretic response and hemoconcentration compared with all other patients.

conclusionsCombining 2 indicators of decongestion, hemoconcentration and diuretic response improves risk prediction for early rehospitalization after an admission for acute HF and may provide clinicians with an easily accessible tool to identify low-risk patients. CLINICAL

trial registrationURL: http://www.clinicaltrials.gov. Unique identifiers: NCT00354458 and NCT00071331.

Indexed as

Decision Support TechniquesPatient ReadmissionAcute DiseaseAgedAged, 80 and overBenzazepinesBiomarkersDiuresisDiureticsFemaleFurosemideHeart FailureHemoglobinsHumansKaplan-Meier EstimateKidneyBenzazepinesBiomarkersDiureticsFurosemideHemoglobinsrolofyllineTolvaptanXanthinesdiureticsheart failurehemoglobinhospitalization

Identifiers

PMID27266853
OpenAlexW2411952446

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.